Immunovant, Inc. — Director's Dealing 2022

Jul 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2022-06-29

Reporting Person: Salzmann Peter (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-29	Common Stock	S	1376	$4.02	Disposed	554259	Direct

Footnotes

F1: On March 19, 2021, the holder was granted 132,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 2,761 of these RSUs vested on June 19, 2022. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.

F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.02 - $4.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.